Real life data of MRI-targeted biopsy - experience from a single nonacademic centre using cognitive fusion and 1.5 tesla scanning.
CONCLUSION: Systematic biopsies should still be considered in patients with PI-RADS 1/2 findings. Our findings also suggest a stronger benefit of the combined strategy of targeted and systematic biopsies than the findings of previous studies concerning the detection of CSPCa in biopsy-naïve patients. PMID: 32865086 [PubMed - as supplied by publisher]
In this study of Chinese men with biochemical recurrence, added value for the detection of lesions compatible with sites of PCa was found with68Ga-PSMA-11 PET/CT over conventional imaging. The observed patterns of disease spread may have implications for understanding the biology of early prostate cancer metastasis.
Conclusion: Ultrahypofractionated radiotherapy, delivered with flattening filter free-volumetric modulated arc therapy and gated by electromagnetic transponders, is a valid option for intermediate-risk prostate cancer.
Conclusion: Repeatability measurements for PET/CT test–retests with 68Ga-PSMA-HBED-CC showed a wCV of 12%–14% SUVmax and an RC of ±33%–38% SUVmax in bone and nodal lesions. These estimates are an important aspect of 68Ga-PSMA-HBED-CC as a quantitative imaging biomarker. These estimates are similar to those reported for 18F-FDG, suggesting that 68Ga-PSMA-HBED-CC PET/CT may be useful in monitoring response to therapy.
Conclusions: 68Ga PSMA PET/CT provides a novel imaging modality for the detection of prostate cancer recurrence and metastases at low posttreatment PSA levels, which may help in directing appropriate salvage treatments.
CONCLUSION: 18F-choline PET/CT could be a useful technique in the group of patients with biochemical recurrence after brachytherapy, providing locoregional and distant involvement findings which had not been detected with conventional imaging tests, thus determining a more adequate therapeutic management. PMID: 32576406 [PubMed - as supplied by publisher]
99mTc-MIBI has long been used to localize hyperfunctioning parathyroid tissue in patients with hyperparathyroidism. This tracer can also concentrate in various neoplastic tissues including prostate adenocarcinoma. We herein report a case with parathyroid hormone-secreting metastatic prostate cancer mimicking an ectopic parathyroid adenoma on the 99mTc-MIBI scan. We conclude that metastatic prostate cancer should be included as one of the differential diagnoses when interpreting 99mTc-MIBI scan.
Conclusions: 68Ga PSMA-11 PET/MR is overall highly concordant with surgical pathology and provides complementary information to multiparametric MR for assessment of extent of cancer involvement in prostate gland and pelvic nodes. Patients without nodal involvement on PET in our cohort had a low probability of biochemical recurrence in two years after imaging.
Conclusions: 64Cu-DOTHA2-PSMA can be synthesized faster and more easily than 64Cu-DOTA-PSMA, while also being more stable. Provisional results predicted 64Cu-DOTHA2-PSMA’s pertinence for imaging and therapy. This radiotracer permits the use of an isotope with a longer half-life than 68Ga for potentially better PET imaging while also being available in Canada for therapy, in opposition to 177Lu. This could offer better PC metastasis diagnosis and treatment for patients. With this preclinical study, we aim to confirm ability to produce images of PC metastases. We also aim to provide evidence, in a pre-clinical model, o...
37Introduction: Bone is the most common site of distant metastatic spread in prostate adenocarcinoma. Prostate-specific membrane antigen uptake has been described in both benign and malignant bone lesions, which can lead to false-positive findings on 68Ga-PSMA-11 positron emission tomography (PSMA PET). The purpose of this study was to evaluate the diagnostic accuracy of PSMA PET for osseous prostate cancer metastases and develop guidelines for interpretation of osseous uptake. Methods: 56 prostate cancer patients (18 pre-prostatectomy, 38 biochemical recurrence) who underwent 68Ga-PSMA-11 PET/MRI or PET/CT examinations wi...
Conclusion: PET/CT has proven to be an effective tool in guiding the use of specific targets for drug delivery to spontaneously occurring disease. The result of this work validates results shown in previous mice studies. Comparative oncology enables researches to further understand the mechanisms of human disease and fast-track drug development. The utility of HBP as a transport mechanism for chemotherapy drugs using PET/CT to determine personalised targets is currently being investigated in canine models.